2-ethoxy-1,3-benzoxazol-6-ol | 439085-77-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 2-ethoxy-1,3-benzoxazol-6-ol
• 英文别名: 2-ethoxy-6-hydroxybenzoxazole
• CAS: 439085-77-5
• 化学式: C₉H₉NO₃
• 分子量: 179.175
• InChiKey: ITXDEUCONLATQR-UHFFFAOYSA-N

物化性质

• 沸点：
  302.9±34.0 °C(Predicted)
• 密度：
  1.293±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  55.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-ethoxy-1,3-benzoxazol-6-ol 、 1-(4-(3-bromopropoxy)phenyl)ethan-1-one 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 7.0h， 以49%的产率得到1-(4-{3-[(2-ethoxy-1,3-benzoxazol-6-yl)oxy]propoxy}phenyl)ethanone
  参考文献：
  名称：

  Synthesis of new compounds with promising antiviral properties against group A and B Human Rhinoviruses

  摘要：

  The human common cold, which is a benign disease caused by the Rhinoviruses, generally receives palliative symptomatic treatments, since no specific therapy against any of these viruses currently exists. In this work, some original synthetic compounds were produced and tested, in order to find non-toxic substances with an improved protection index (PI) for infected cells, as compared to reference drugs such as Pirodavir. We designed a series of novel molecules with a double oxygen in the central hydrocarbon chain and some modifications of the lateral methylisoxazole and propoxybenzoate moieties of lead compound 6602 (ethyl 4-{3-[2-(3-methyl-1,2-isoxazol-5-yl)ethoxy]propoxy)benzoate). It was found that most of these substances were actually less toxic than Pirodavir; in addition, the new molecule indicated as 8c was more than 30 times less toxic than Pirodavir, about twice as active on the group A strain of Rhinovirus HRV14, and even four times more effective on the group B strain HRV39, as compared to Pirodavir's PI. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.05.066
• 作为产物：
  描述：

  原碳酸四乙酯 、 4-氨基间苯二酚 盐酸盐 在 sodium acetate 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以60%的产率得到2-ethoxy-1,3-benzoxazol-6-ol
  参考文献：
  名称：

  Antiviral agents

  摘要：

  本发明涉及式I化合物及其盐，以及药用上可接受的衍生物，包括这些化合物的药物组合物，以及它们在哺乳动物的小肠病毒感染治疗中的应用，以及在制备式I化合物中有用的新中间体。

  公开号：

  US09303026B2

文献信息

• Antiviral agents
  申请人：——

  公开号：US20040077633A1

  公开（公告）日：2004-04-22

  This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals as well as novel intermediates useful in the preparation of the compounds of formula I. 1

  这项发明涉及公式I的化合物及其盐，以及药学上可接受的衍生物，包括这些化合物的药物组合物以及它们在治疗哺乳动物的小RNA病毒感染中的用途，以及在制备公式I化合物中有用的新型中间体。
• [EN] ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX
  申请人：BIOTA SCIENT MANAGEMENT

  公开号：WO2002050045A1

  公开（公告）日：2002-06-27

  This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals as well as novel intermediates useful in the preparation of the compounds of formula I.

  本发明涉及公式I的化合物及其盐，以及药学上可接受的衍生物，包括这些化合物的制药组合物和它们在哺乳动物的小肠病毒感染治疗中的应用，以及制备公式I化合物的新中间体。
• ANTIVIRAL AGENTS
  申请人：Watson Keith

  公开号：US20090030000A1

  公开（公告）日：2009-01-29

  This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals, as well as novel intermediates useful in the preparation of the compounds of formula I.

  本发明涉及公式I的化合物及其盐和药学上可接受的衍生物，包括这些化合物的制药组合物和它们在哺乳动物的小肠病毒感染治疗中的用途，以及在制备公式I化合物中有用的新型中间体。
• Heterocyclic compounds as antiviral agents
  申请人：Biota Scientific Management Pty Ltd

  公开号：EP2314582A1

  公开（公告）日：2011-04-27

  This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals as well as novel intermediates useful in the preparation of the compounds of formula I.

  本发明涉及式 I 化合物、其盐类和药学上可接受的衍生物、包含这些化合物的药物组合物及其在治疗哺乳动物皮卡病毒感染中的用途，以及用于制备式 I 化合物的新型中间体。
• EP1353911A4
  申请人：——

  公开号：EP1353911A4

  公开（公告）日：2005-01-05